TNSN07425A1 - Combinaison pharmaceutique comprenant un agent antifongique et un actif choisi parmi le carveol,l'eugenol, le thymol, le borneol, le carvacrol, et les ionones alpha-et-beta-. - Google Patents

Combinaison pharmaceutique comprenant un agent antifongique et un actif choisi parmi le carveol,l'eugenol, le thymol, le borneol, le carvacrol, et les ionones alpha-et-beta-.

Info

Publication number
TNSN07425A1
TNSN07425A1 TNP2007000425A TNSN07425A TNSN07425A1 TN SN07425 A1 TNSN07425 A1 TN SN07425A1 TN P2007000425 A TNP2007000425 A TN P2007000425A TN SN07425 A TNSN07425 A TN SN07425A TN SN07425 A1 TNSN07425 A1 TN SN07425A1
Authority
TN
Tunisia
Prior art keywords
carveol
carvacrol
borneol
thymol
eugenol
Prior art date
Application number
TNP2007000425A
Other languages
English (en)
French (fr)
Inventor
Adnane Remmal
Original Assignee
Advanced Scient Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Scient Dev filed Critical Advanced Scient Dev
Publication of TNSN07425A1 publication Critical patent/TNSN07425A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TNP2007000425A 2005-05-13 2007-11-13 Combinaison pharmaceutique comprenant un agent antifongique et un actif choisi parmi le carveol,l'eugenol, le thymol, le borneol, le carvacrol, et les ionones alpha-et-beta-. TNSN07425A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IB2005/001317 WO2006120496A1 (fr) 2005-05-13 2005-05-13 Combinaison pharmaceutique comprenant un agent antifongique et un actif choisi parmi le carveol, l’ eugenol, le thymol, le borneol, et le carvacrol
PCT/IB2006/001329 WO2006120565A2 (fr) 2005-05-13 2006-05-15 Combinaison pharmaceutique comprenant un agent antifongique et un actif choisi parmi le carveol, l'eugenol, le thymol, le borneol, le carvacrol, et les i0n0nes alpha- et beta-.

Publications (1)

Publication Number Publication Date
TNSN07425A1 true TNSN07425A1 (fr) 2009-03-17

Family

ID=35427301

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2007000425A TNSN07425A1 (fr) 2005-05-13 2007-11-13 Combinaison pharmaceutique comprenant un agent antifongique et un actif choisi parmi le carveol,l'eugenol, le thymol, le borneol, le carvacrol, et les ionones alpha-et-beta-.

Country Status (13)

Country Link
US (1) US20080214568A1 (enExample)
EP (1) EP1879654B1 (enExample)
JP (1) JP5410747B2 (enExample)
CN (1) CN101189044B (enExample)
BR (1) BRPI0610132B8 (enExample)
CA (1) CA2607561C (enExample)
DK (1) DK1879654T3 (enExample)
EA (1) EA014068B1 (enExample)
ES (1) ES2390472T3 (enExample)
MA (1) MA29907B1 (enExample)
PT (1) PT1879654E (enExample)
TN (1) TNSN07425A1 (enExample)
WO (2) WO2006120496A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1806982T3 (en) 2004-09-28 2018-11-19 Avivagen Inc COMPOSITIONS AND PROCEDURES FOR PROMOTING WEIGHT ADMINISTRATION AND FOOD TRAFFIC
US10449247B2 (en) 2007-10-26 2019-10-22 Avivagen Inc. Compositions and methods for enhancing immune response
AU2010242502B2 (en) 2009-04-30 2016-11-10 Avivagen Inc. Methods and compositions for improving the health of animals
WO2011036048A1 (en) 2009-09-24 2011-03-31 Unilever Nv Disinfecting agent comprising eugenol, terpineol and thymol
EP2648681B1 (en) 2010-12-07 2015-01-07 Unilever N.V. An oral care composition
CN102550610B (zh) * 2010-12-07 2014-12-10 菲勒斯株式会社 含有从红松球果中提取的植物杀菌素的天然抗菌剂及包含它的水果病害防除原料
CN103347407A (zh) * 2011-02-07 2013-10-09 弗门尼舍有限公司 抗真菌调味成分和组合物
EP2773315B1 (en) 2011-11-03 2015-07-08 Unilever N.V. A personal cleaning composition
JP5925605B2 (ja) * 2012-06-04 2016-05-25 花王株式会社 リパーゼ活性阻害剤、抗真菌剤、及びフケ抑制剤
IL251588B2 (en) * 2014-10-08 2024-09-01 Pacific Northwest Res Institute Methods and compositions for increasing the potency of antifungal agents
CN104642326B (zh) * 2015-02-16 2016-02-10 河南科技学院 一种含戊苯吡菌胺和香芹酚的杀菌组合物及其用途
CN109562182A (zh) 2016-06-02 2019-04-02 先进科学发展公司 包含桉树脑和阿莫西林的药物制剂
US10918647B2 (en) 2016-07-26 2021-02-16 University Of Southern California Selective bromodomain inhibition of fungal Bdf1
CN113116916B (zh) * 2021-05-25 2023-07-04 河北医科大学第二医院 一种治疗妇科疾病的药物组合物及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5627153A (en) * 1994-01-14 1997-05-06 Xoma Corporation Anti-fungal methods and materials
US5294645A (en) * 1993-06-14 1994-03-15 Doyle E. Chastain Using menth-1-en-9-ol to kill bacteria, yeast, and fungi
CA2106032C (en) * 1993-09-13 1995-11-07 Gamini Weeratunga Methods for the manufacture of fluconazole and forms thereof, intermediates useful in the manufacture thereof, and combinations comprising fluconazole
EP0831870A4 (en) * 1995-06-07 1998-09-16 Avmax Inc USE OF ESSENTIAL OILS TO INCREASE THE BIOAVAILABILITY OF ORAL PHARMACEUTICAL COMPOUNDS
US6319507B1 (en) * 1997-05-02 2001-11-20 Kobo Products, Inc. Agar gel bead composition and method
US6414036B1 (en) * 1999-09-01 2002-07-02 Van Beek Global/Ninkov Llc Composition for treatment of infections of humans and animals
AU2002217316A1 (en) * 2001-01-03 2002-07-30 Medpharma Plc Use of terpenes for the treatment of digestive tract infections
JP2002284702A (ja) * 2001-01-19 2002-10-03 Teika Seiyaku Kk 外用抗真菌製剤
US20030064948A1 (en) * 2001-02-08 2003-04-03 Alfred Fahr Invasomes for therapy of disorders, their preparation and use
JP2002363070A (ja) * 2001-06-06 2002-12-18 Yuutoku Yakuhin Kogyo Kk 経皮吸収貼付剤
US20040071757A1 (en) * 2001-11-20 2004-04-15 David Rolf Inhalation antiviral patch
US20030180349A1 (en) * 2001-12-07 2003-09-25 Franklin Lanny U. Respiratory infection prevention and treatment with terpene-containing compositions
US20030225003A1 (en) * 2002-04-18 2003-12-04 Dusan Ninkov Antimicrobial therapeutic compositions for oral and topical use
US20040151771A1 (en) * 2003-02-04 2004-08-05 Gin Jerry B. Long-lasting, flavored dosage forms for sustained release of beneficial agents within the mouth
US20050014730A1 (en) * 2003-04-02 2005-01-20 Carlson Robert M. Anti-fungal formulation of triterpene and essential oil

Also Published As

Publication number Publication date
EP1879654B1 (fr) 2012-07-04
JP5410747B2 (ja) 2014-02-05
WO2006120496A1 (fr) 2006-11-16
PT1879654E (pt) 2012-08-29
CN101189044B (zh) 2011-12-07
BRPI0610132A2 (pt) 2012-09-25
JP2008540506A (ja) 2008-11-20
WO2006120565A2 (fr) 2006-11-16
CA2607561C (fr) 2014-02-04
CN101189044A (zh) 2008-05-28
WO2006120565A3 (fr) 2007-08-23
EA200702482A1 (ru) 2008-04-28
EA014068B1 (ru) 2010-08-30
DK1879654T3 (da) 2012-08-20
CA2607561A1 (fr) 2006-11-16
US20080214568A1 (en) 2008-09-04
BRPI0610132B8 (pt) 2021-05-25
MA29907B1 (fr) 2008-11-03
BRPI0610132B1 (pt) 2020-08-11
EP1879654A2 (fr) 2008-01-23
ES2390472T3 (es) 2012-11-13

Similar Documents

Publication Publication Date Title
TNSN07425A1 (fr) Combinaison pharmaceutique comprenant un agent antifongique et un actif choisi parmi le carveol,l'eugenol, le thymol, le borneol, le carvacrol, et les ionones alpha-et-beta-.
TNSN07424A1 (fr) Combinaison pharmaceutique comprenant un antibacterien et une substance active choisie parmi le carveol, le thymol, l'eugenol, le borneol et le carvacrol
TNSN07423A1 (fr) Composition pharmaceutique comprenant un agent antiparasitaire, et un actif choisi parmi le carveol, le thymol, l'eugenol, le borneol, le carvacrol, l 'alpha-ionone ou le beta-ionone
WO2003105800A3 (de) Filmförmige mucoadhäsive darreichungsformen zur verabreichung von cannabis-wirkstoffen
MA30504B1 (fr) Compositions pharmaceutiques stabilisees comprenant de la fesoterodine
WO2006017251A3 (en) Compositions for delivering peptide yy and pyy agonists
WO2004104018A3 (en) Compositions for delivering peptide yy and pyy agonists
NO20043367L (no) Oralt farmasoytisk preparat
MA27729A1 (fr) Compositions pharmaceutiques solides contenant un agoniste des recepteurs de la s1p et un alcool de sucre
ATE534383T1 (de) Zusammensetzungen aus n-ä2,4-bis(1,1- dimethylethyl)-5-hydroxyphenylü-1,4-dihydro-4- oxochinolin-3-carboxamid
MA30765B1 (fr) Derives innovants du thiophene
NO20025601D0 (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
WO2006081363A3 (en) Oral formulations for delivery of catecholic butanes including ndga compounds
TNSN08152A1 (fr) Composition a liberation prolongee de l'actif, son procede de preparation et son utilisation
MA29723B1 (fr) Composes
DK1296972T3 (da) Arylmethylamin-derivater til anvendelse som tryptaseinhibitorer
MA29969B1 (fr) Formulations de quinolinones
WO2005117895A8 (en) Compositions comprising meloxicam
WO2004087167A3 (en) Pharmaceutical compositions comprising epinastine for the treatment of skin diseases
MA29333B1 (fr) Preparations pharmaceutiques d'aerosol pour aerosols-doseurs pressurises contenant un agent sequestrant
DK1906916T3 (da) Oftalmisk suspension, der omfatter et oftalmisk lægemiddel, en poloxamin og et tonicitetsregulerende glycolbaseret middel, anvendelse af sammensætningen til fremstilling af et medikament til behandling af oftalmiske lidelser
WO2005037755A3 (en) Bridged ring structures as pharmaceutical agents
NO20064808L (no) Orale matrixformuleringer med licarbazepin
WO2007009691A3 (en) Combination of substituted pyrazolines and anti -addictive agent
WO2007011958A3 (en) Intraoral dosage forms of glucagon